HER-2/neu表位肿瘤疫苗研究进展

doi:10.12092/j.issn.1009-2501.2019.09.013

摘要/Abstract

摘要：

原癌基因HER-2/neu（human epidermal growth factor receptor type 2）在乳腺癌（20%～40%）、结直肠癌（54%～100%）、卵巢癌（25%）等多种肿瘤中有扩增或过表达，故HER-2/neu蛋白是肿瘤候选靶标抗原之一，且已被证明具有开发抗乳腺癌疫苗的潜力。目前针对不同类型的HER-2疫苗，包括全细胞疫苗、全序列蛋白疫苗、肽疫苗、树突状细胞（DC）相关疫苗以及基因疫苗等展开了一系列研究，并取得一定进展。该文通过检索百度学术，PubMed，Springer以及ScienceDirect数据库，对近年来HER-2/neu肿瘤疫苗的制备及其抗肿瘤活性机制的研究进展进行综述。HER-2/neu肿瘤疫苗经抗原递呈细胞(APCs)展示，能够有效地激活CD4+T和CD8+T，并诱导特异性抗肿瘤免疫应答反应，其结构及组成佐剂的改变、融合表达以及DC诱导等疫苗设计工艺改变，能够显著地提高疫苗的免疫活性和抗肿瘤活性。HER-2疫苗在临床试验研究中发现能够有效地降低抗体药物治疗所致的耐药性，反复用药以及其它化疗药物的严重毒副作用等缺陷，并有效稳定地发挥抗肿瘤活性，为肿瘤的治疗提供一个崭新的视角。

关键词: HER-2/neu, 肿瘤疫苗, 树突状细胞, 免疫活性

Abstract:

Overexpression of HER-2/neu oncogene is a frequent molecular event in multiple human cancer, including breast cancer (20%-40%), colorectal cancer (54%-100%), ovarian cancer (25%). Therefore, HER-2/neu protein is one of the candidate target antigens for cancer, and has been proved to have the potential to develop anti-breast cancer vaccines. At present, a series of studies have been carried out on different types of HER-2 vaccines, including whole-cell vaccines, full-sequence protein vaccines, peptide vaccines and DC-induced vaccines, and some progress has been made. A baidu Scholar, PubMed, Springer and ScienceDirect database search was performed to review the advanced of the preparation technology and the mechanism of antineoplastic activity of tumor vaccine based on HER-2/neu antigen. As the conclusions shown in the present paper, CD4+T and CD8+T were activated successfully and the anti-tumor specific immune response was induced by the antigen presenting cells (APCs) presented with the HER-2/neu tumor vaccine antigenic epitope. The immunological and anti-tumor activity would be improved by the change of vaccine design process, such as the reform of composition structure, fusion expression with immune-boosting short peptides and dendritic cell induced. The defect of drug resistance and repeated administration accompanied by HER-2 monoclonal antibody treatment and the serious toxicity of traditional chemotherapy drugs treatment could be reduced by HER-2 anti-tumor vaccine treatment with the stable anti-tumor activity in the clinic trail, which would provide a new perspective of tumor treatment.

Key words: HER-2/neu, tumor vaccine, dendritic cell, immune activity

中图分类号:

R730.51

林忠，谢群莉，李胜英，金慧，徐芬芬，谢丽云，蒋正立. HER-2/neu表位肿瘤疫苗研究进展[J]. 中国临床药理学与治疗学, 2019, 24(9): 1046-1052.

LIN Zhong, XIE Qunli, LI Shengying, JIN Hui, XU Fenfen, XIE Liyun, JIANG Zhengli. Advanced of HER-2/neu epitope anti-tumor vaccine[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(9): 1046-1052.

参考文献

［1］Couzin-Frankel J. Breakthrough of the year "Cancer Immunotherapy"［J］. Science, 2013, 342(6165): 1432-1433.
［2］Garber K. Driving T-cell immunotherapy to solid tumors［J］. Nat Biotechnol, 2018, 36(3): 215-219.
［3］Schaller TH, Sampson JH. Advances and challenges: dendritic cell vaccination strategies for glioblastoma［J］. Expert Rev Vaccines, 2017, 16(1): 27-36.
［4］王艳梅, 陈坤, 曲春枫. 肿瘤疫苗的研究进展［J］. 国际免疫学杂志, 2018, 41(6): 683-689.
［5］Shin SH, Park SS, Ju EJ, et al. Establishment of a patient-derived xenograft for development of personalized HER-2-targeting therapy in gastric cancer［J］. Anticancer Res, 2018, 38(1): 287-293.
［6］Shang AQ, Wu J, Bi F, et al. Relationship between HER-2 and JAK/STAT-SOCS3 signaling pathway and clinicopathological features and prognosis of ovarian cancer［J］. Cancer Biol Ther, 2017, 18(5): 314-322.
［7］Subbarayan K, Leisz S, Wickenhauser C, et al. Biglycan-mediated upregulation of MHC class I expression in HER-2/neu-transformed cells［J］. Oncoimmunology, 2018, 7(4): e1373233.
［8］Kimball A, Patil S, Koczwara B, et al. Late characterisation of cardiac effects following anthracycline and trastuzumab treatment in breast cancer patients［J］. Int J Cardiol, 2018, 261159-261161.
［9］Liu W, Zhai X, Wang W, et al. Aldehyde dehydrogenase 2 activation ameliorates cyclophosphamide-induced acute cardiotoxicity via detoxification of toxic aldehydes and suppression of cardiac cell death［J］. J Mol Cell Cardiol, 2018, 121134-121144.
［10］Costa RLB, Soliman H, Czerniecki BJ. The clinical development of vaccines for HER-2(+) breast cancer: Current landscape and future perspectives［J］. Cancer Treat Rev, 2017, 61107-61115.
［11］赵丽丽, 姜北海, 寿成超. HER-2/neu肿瘤疫苗的研究进展［J］. 中国肿瘤生物治疗杂志, 2010, 17(2): 221-226.
［12］Di Leo A, Johnston S, Lee KS, et al. Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER-2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial［J］. Lancet Oncol, 2018, 19(1): 87-100.
［13］Adamczyk A, Grela-Wojewoda A, Domagala-Haduch M, et al. Proteins involved in HER-2 signalling pathway, their relations and influence on metastasis-free survival in HER-2-positive breast cancer patients treated with trastuzumab in adjuvant setting［J］. J Cancer, 2017, 8(1): 131-139.
［14］He Y, Rozeboom L, Rivard CJ, et al. MHC class II expression in lung cancer［J］. Lung Cancer, 2017, 11275-11280.
［15］Smahel M. PD-1/PD-L1 blockade therapy for tumors with downregulated MHC class I expression［J］. Int J Mol Sci, 2017, 18(6), doi: 10.3390/ijms18061331.
［16］Lee JH, Son YH, Kwon YW, et al. Anticancer effects of a Korean herbal medicine formula (H9) via AMPK and HER-2-PI3K/Akt signaling in breast cancer cells［J］. Phytother Res, 2017, 31(11): 1765-1775.
［17］Pupa SM, Invernizzi AM, Forti S, et al. Prevention of spontaneous neu-expressing mammary tumor development in mice transgenic for rat proto-neu by DNA vaccination［J］. Gene Therapy, 2001, 8(1): 75-79.
［18］Smorlesi A, Papalini F, Amici A, et al. Evaluation of different plasmid DNA delivery systems for immunization against HER-2/neu in a transgenic murine model of mammary carcinoma［J］. Vaccine, 2006, 24(11): 1766-1775.
［19］Falk K, Rtzschke O, Stevanovic S, et al. Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules［J］. Nature, 1991, 351(6324): 290-296.
［20］陈龙冠, 宋燕, 许元生, 等. 针对HER-2的多肽疫苗CKL9与YL20的抗肿瘤活性研究［J］. 中国药理学通报，2017, 33(7): 997-1002.
［21］Amin A, Benavides LC, Holmes JP, et al. Assessment of immunologic response and recurrence patterns among patients with clinical recurrence after vaccination with a preventive HER-2/neu peptide vaccine: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02［J］. Can Immunol Immunothera, 2008, 57(12): 1817-1825.
［22］Khoo S, Storrer C, Harris K, et al. Early results of a phase I clinical trial of an Ii-Key/HER-2/neu MHC Class II peptide-based vaccine in breast cancer patients［J］. J Am Col Surg, 2006, 203(3): S81.
［23］Gates JD, Carmichael MG, Benavides LC, et al. Longterm followup assessment of a HER-2/neu peptide (E75) vaccine for prevention of recurrence in high［J］. J Am Col Surg, 2009, 208(2): 193-201.
［24］Patil R, Clifton GT, Holmes JP, et al. Clinical and immunologic responses of HLA-A3+ breast cancer patients vaccinated with the HER-2/neu-derived peptide vaccine, E75, in a phase I/II clinical trial［J］. J Am Col Surg, 2010, 210(2): 140-147.
［25］Disis ML, Gooley TA, Kristine R, et al. Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines［J］. J Clin Oncol Off J Am Soc Clin Oncol, 2002, 20(11): 2624-2632.
［26］龙敏, 董柯, 王希, 等. HER-2/ECD-sf162/TM嵌合VLPs的制备及抗肿瘤免疫效果研究［J］. 现代肿瘤医学，2016, 24(21): 3355-3359.
［27］ML D, DR W, TA G, et al. Concurrent trastuzumab and HER-2/neu-specific vaccination in patients with metastatic breast cancer［J］. J Clin Oncol, 2009, 27(28): 4685-4692.
［28］Norell H, Poschke I, Charo J, et al. Vaccination with a plasmid DNA encoding HER-2/neu together with low doses of GM-CSF and IL-2 in patients with metastatic breast carcinoma: a pilot clinical trial［J］. J Transl Med, 2010, 8(6): 53.
［29］Aoki M, Ueda S, Nishikawa H, et al. Antibody responses against NY-ESO-1 and HER-2 antigens in patients vaccinated with combinations of cholesteryl pullulan (CHP)-NY-ESO-1 and CHP-HER-2 with OK-432［J］. Vaccine, 2009, 27(49): 6854-6861.
［30］Danko JR, Kochel T, Teneza-Mora N, et al. Safety and immunogenicity of a tetravalent dengue DNA vaccine administered with a cationic lipid-based adjuvant in a phase 1 clinical trial［J］. Am J Trop Med Hyg, 2018, 98(3): 849-856.
［31］Vacchelli E, Galluzzi L, Eggermont A, et al. Trial watch: FDA-approved toll-like receptor agonists for cancer therapy［J］. Oncoimmunol, 2012, 1(6): 894-907.
［32］Sheida S, Ali B, Seyed Amir J, et al. P5 HER-2/neu-derived peptide conjugated to liposomes containing MPL adjuvant as an effective prophylactic vaccine formulation for breast cancer［J］. Cancer Letters, 2014, 355(1): 54-60.
［33］Jang JE, Hajdu CH, Liot C, et al. Crosstalk between regulatory T cells and tumor-associated dendritic cells negates anti-tumor immunity in pancreatic cancer［J］. Cell Rep, 2017, 20(3): 558-571.
［34］Shang N, Figini M, Shangguan J, et al. Dendritic cells based immunotherapy［J］. Am J Cancer Res, 2017, 7(10): 2091-2102.
［35］Rosenthal KS, Stone S, Koski G, et al. LEAPS vaccine incorporating HER-2/neu epitope elicits protection that prevents and limits tumor growth and spread of breast cancer in a mouse model［J］. J Immunol Res, 2017, 20173613505.
［36］冯喆, 张剑, 李文桦, 等. 术前应用HER2特异性树突状细胞疫苗治疗导管原位癌患者的安全性和有效性评估［J］. 循证医学, 2018, 18(3): 137-139.
［37］戴辉腾, 田浤, 黄捷, 等. 含对硝基苯丙氨酸的B淋巴细胞刺激因子疫苗对狼疮肾炎模型小鼠的保护作用［J］. 中国药科大学学报, 2017, 48(4): 483-489.
［38］蔡棣, 田浤, 姚文兵. 含有L-对硝基苯丙氨酸的BAFF改构体的分子动力学模拟与分析［J］. 中国药科大学学报, 2017, 48(2): 227-232.

[1]	黄好, 贾虹, 王晓霜, 张鹭, 蒋华. 负载MAGE-A3抗原的树突状细胞与细胞因子诱导杀伤细胞共培养对子宫内膜癌肿瘤干细胞及恶性进展的影响[J]. 中国临床药理学与治疗学, 2023, 28(1): 42-50.
[2]	胡玉平，周海云，黄巧玲，姚轶敏. 丹皮酚对FSL-1与IL-4共刺激诱导树突状细胞成熟及细胞因子表达的影响[J]. 中国临床药理学与治疗学, 2019, 24(1): 14-19.
[3]	陈叶，贺守第，胡智立，冯斌. 香菇多糖对卵白蛋白诱导小鼠哮喘模型树突细胞TIM4表达及炎症影响[J]. 中国临床药理学与治疗学, 2018, 23(9): 998-1002.
[4]	唐余燕, 李丹, 余永胜. 浆细胞样树突状细胞(pDCs)在慢性乙肝中的研究进展[J]. 中国临床药理学与治疗学, 2012, 17(9): 1062-1066.
[5]	刘红红, 陈小华, 周丽芹, 刘雪妮, 余永胜, 臧国庆, 汤正好. CTP-HBcAg18-27-Tapasin融合蛋白胞内转导功能的检测[J]. 中国临床药理学与治疗学, 2012, 17(1): 25-29.
[6]	王琼, 朱学军. 黄芪多糖促进人树突状细胞体外分化成熟的实验研究[J]. 中国临床药理学与治疗学, 2010, 15(12): 1348-1352.
[7]	何秀娟, 张罕, 李冬妹, 邱勇, 龙军, 安云庆, 胡永秀. 西罗莫司对小鼠树突状细胞CD₈₆、I-A^b和Toll样受体4表达的影响[J]. 中国临床药理学与治疗学, 2010, 15(10): 1133-1138.
[8]	伍香玲, 何小魁, 李波, 胡永秀. 地塞米松对树突状细胞Toll 样受体4信号通路的影响[J]. 中国临床药理学与治疗学, 2009, 14(9): 1023-1027.
[9]	何小魁, 胡永秀. 地塞米松诱导产生耐受性树突状细胞的机制[J]. 中国临床药理学与治疗学, 2009, 14(1): 113-116.
[10]	王桂平, 刘新艳, 朱柳, 余清声. 抗眼镜王蛇毒卵黄抗体的免疫活性及其对眼镜王蛇毒的中和作用[J]. 中国临床药理学与治疗学, 2007, 12(11): 1250-1254.
[11]	李慧, 王丙力, 毛一卿, 张翼, 李志红, 申淑兰, 谭焕然. 匹多莫德对免疫功能缺陷小鼠脾组织TNF-α和IL-6表达及相关免疫药理作用的研究[J]. 中国临床药理学与治疗学, 2005, 10(8): 857-862.